Department of Radiology, University of Washington School of Medicine, 1959 NE Pacific Street, Box 357115, Seattle, WA, 98195, USA.
Department of Medicine, Division of Oncology, University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA, 98195, USA.
Abdom Radiol (NY). 2021 May;46(5):1992-2002. doi: 10.1007/s00261-020-02786-y. Epub 2020 Oct 20.
To evaluate the feasibility of CT perfusion performed during routine multiphase contrast-enhanced CT on a 160 mm wide-coverage 256-slice scanner in patients with pancreatic ductal adenocarcinoma (PDAC).
Fifty-seven patients had a CT perfusion acquisition during their routine multiphase CT. Perfusion was performed 5 to 42.5 s (15 passes at 2.5 s intervals) after intravenous contrast administration (4.2-5 ml/s), followed by pancreatic parenchymal and portal venous phases for clinical interpretation. Perfusion maps were generated and blood flow (BF), blood volume (BV), and permeability surface area product (PS) for tumor and uninvolved pancreas were calculated using deconvolution algorithms and compared to existing similar publications. Radiation dose information was recorded and size-specific dose estimate (SSDE) was calculated using body dimensions.
Diagnostic quality of standard images was unaffected by performing the perfusion acquisition. Average tumor center BF was 20.8 ± 12.1 ml/100 g/min, BV 2.5 ± 2.1 ml/100 g and PS 15.5 ± 39.4 ml/100 g/min. Average pancreas BF was 90.8 ± 50.2 ml/100 g/min, BV 11.9 ± 4.3 ml/100 g and PS 33.6 ± 27.7 ml/100 g/min. For the perfusion acquisition, mean SSDE was 57 ± 11 mGy, CTDI 43 ± 6 mGy and DLP 685 ± 100 mGy-cm.
Adding a perfusion CT acquisition to standard pancreatic CT protocol is feasible using a wide-detector 256-slice CT scanner and adds quantitative information while maintaining diagnostic quality of the standard of care examination. This novel protocol adds no time or cost to the examination and yields perfusion parameters that are comparable to existing literature using a separate dedicated perfusion protocol.
在使用宽探测器 256 层 CT 扫描仪对胰腺导管腺癌(PDAC)患者进行常规多期增强 CT 检查期间,评估 CT 灌注的可行性。
57 例患者在常规 CT 检查期间进行 CT 灌注采集。静脉内对比剂注射后 5 至 42.5 s(15 次 2.5 s 间隔)进行灌注,随后进行胰腺实质和门静脉期以进行临床解读。使用去卷积算法生成灌注图,并计算肿瘤和未受累胰腺的血流量(BF)、血容量(BV)和渗透表面积乘积(PS),并与现有类似文献进行比较。记录辐射剂量信息,并使用身体尺寸计算体型特异性剂量估计(SSDE)。
进行灌注采集并未影响标准图像的诊断质量。平均肿瘤中心 BF 为 20.8±12.1 ml/100 g/min,BV 为 2.5±2.1 ml/100 g,PS 为 15.5±39.4 ml/100 g/min。平均胰腺 BF 为 90.8±50.2 ml/100 g/min,BV 为 11.9±4.3 ml/100 g,PS 为 33.6±27.7 ml/100 g/min。对于灌注采集,平均 SSDE 为 57±11 mGy,CTDI 为 43±6 mGy,DLP 为 685±100 mGy-cm。
使用宽探测器 256 层 CT 扫描仪为标准胰腺 CT 方案添加灌注 CT 采集是可行的,在保持标准护理检查诊断质量的同时提供定量信息。这种新方案不会增加检查的时间或成本,并且可以产生与使用单独的专用灌注方案的现有文献相当的灌注参数。